Peptide-Oligonucleotide Hybrids in Antisense Therapy

Authors: Tracie L. Pierce; Anthony R. White; Geoffrey W. Tregear; Patrick M. Sexton

Source: Mini Reviews in Medicinal Chemistry, Volume 5, Number 1, January 2005 , pp. 41-55(15)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Antisense technology provides outstanding promise for treatment of human disease, having broad applicability and high specificity. Although advances have been made in antisense oligonucleotide chemistry, leading to increased plasma and cellular stability, and decreased toxicity, considerable potential remains for the enhancement of oligonucleotide uptake for targeted delivery of oligonucleotides. One promising avenue for achieving this is via linkage of antisense oligonucleotides to peptide carriers. This review looks at the current status of developments in this area.

Keywords: antisense therapy; oligonucleotides; nuclear localisation sequences

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389557053402846

Affiliations: 1: Howard Florey Institute, University of Melbourne, Victoria 3010, Australia.

Publication date: 2005-01-01

More about this publication?

The aim of Mini-Reviews in Medicinal Chemistry is to publish short reviews on the important recent developments in medicinal chemistry and allied disciplines.

The scope of Mini-Reviews in Medicinal Chemistry will cover all areas of medicinal chemistry including developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, drug targets, and natural product research and structure-activity relationship studies.

Mini-Reviews in Medicinal Chemistry is an essential journal for every medicinal and pharmaceutical chemist who wishes to be kept informed and up-to-date with the latest and most important developments.